{"DataElement":{"publicId":"6763067","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification Indicator","preferredDefinition":"The response to a question asking if dose modifications to study drug Inotuzumab Ozogamicin were made during a specified reporting period.","longName":"INO_DOSE_MOD_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6763063","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The act of making a change or the change made; changed or altered in form or character.","longName":"5724182v1.0:2207677v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5724182","version":"1","preferredName":"Inotuzumab Ozogamicin","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"C71542","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B52C4CB-AE3E-627C-E053-F662850A0E20","latestVersionIndicator":"Yes","beginDate":"2017-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-22","modifiedBy":"ONEDATA","dateModified":"2017-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207677","version":"1","preferredName":"Dose Modification","preferredDefinition":"The amount of medicine taken, or radiation given, at one time.:Modification; the act of making something different.","longName":"C25488:C25572","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Modification","conceptCode":"C25572","definition":"Modification; the act of making something different.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2C17-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"891CA60C-1174-2777-E053-F662850A4D60","latestVersionIndicator":"Yes","beginDate":"2019-05-17","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-17","modifiedBy":"SETRAKIN","dateModified":"2019-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6763064","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"6763064v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682943","version":"1","preferredName":"No","longName":"5682943","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AC2-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89952458-167B-0F67-E053-F662850A14E9","beginDate":"2019-05-17","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","deletedIndicator":"No"},{"value":"Yes, dose modification not per protocol","valueDescription":"Dose Modification Per Protocol Yes","ValueMeaning":{"publicId":"6767173","version":"1","preferredName":"Dose Modification Per Protocol Yes","longName":"6767173","preferredDefinition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.: For each, generally denoting a ratio.: A rule which guides how an activity should be performed.: The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Per","conceptCode":"C65039","definition":"For each, generally denoting a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89952458-168A-0F67-E053-F662850A14E9","latestVersionIndicator":"Yes","beginDate":"2019-05-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89952458-16A3-0F67-E053-F662850A14E9","beginDate":"2019-05-17","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","deletedIndicator":"No"},{"value":"Yes, dose modification per protocol","valueDescription":"Dose Modification Negation Per Protocol Yes","ValueMeaning":{"publicId":"6767174","version":"1","preferredName":"Dose Modification Negation Per Protocol Yes","longName":"6767174","preferredDefinition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.: An operation in which a term denies or inverts the meaning of another term or construction.: For each, generally denoting a ratio.: A rule which guides how an activity should be performed.: The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Per","conceptCode":"C65039","definition":"For each, generally denoting a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89952458-16B3-0F67-E053-F662850A14E9","latestVersionIndicator":"Yes","beginDate":"2019-05-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89952458-16CC-0F67-E053-F662850A14E9","beginDate":"2019-05-17","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"891CA60C-118B-2777-E053-F662850A4D60","latestVersionIndicator":"Yes","beginDate":"2019-05-17","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-17","modifiedBy":"SETRAKIN","dateModified":"2019-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Were there any Inotuzumab ozo","type":"Preferred Question Text","description":"Were there any Inotuzumab ozogamicin dose reductions or omissions?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"891E1D3A-A779-4125-E053-F662850A7DEC","latestVersionIndicator":"Yes","beginDate":"2019-05-17","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-17","modifiedBy":"SETRAKIN","dateModified":"2019-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}